Anti‐platelet therapy: ADP receptor antagonists
Key result
ADP receptor antagonists targeting the P2Y12 receptor provide effective antithrombotic therapy by inhibiting platelet function, with ongoing research into their specific modes of action.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports P2Y12 antagonists in antithrombotic regimens; leaves open precise modes of action for further study.
Key Points
- To review available and investigational ADP receptor antagonists, evaluate their mechanisms of action, and explore secondary pathways of platelet inhibition.
- Assessed pharmacological profiles of established and investigational agents targeting the platelet P2Y(12) receptor.
- Examined primary antagonist mechanisms and potential secondary cellular pathways influencing platelet activation and inhibition.
- Targeting the P2Y(12) receptor provides potent inhibition of ADP-mediated platelet activation, forming a cornerstone of antithrombotic management.
- Effective therapeutic use requires balancing antithrombotic efficacy against the risk of disrupting normal haemostatic mechanisms.
- Multiple emerging antagonists exhibit distinct pharmacokinetic properties and may involve additional inhibitory mechanisms affecting platelet function.
Structured PICO
I
Intervention
ADP receptor antagonists (P2Y12 inhibitors)
This review summarizes the mechanisms and clinical development of P2Y12 ADP receptor antagonists for antithrombotic therapy.
Cite This Study
Wijeyeratne et al. (2011) conducted a review in Thrombosis. ADP receptor antagonists was evaluated. ADP receptor antagonists targeting the P2Y12 receptor provide effective antithrombotic therapy by inhibiting platelet function, with ongoing research into their specific modes of action.